Information on this site is not intended as medical advice and should not be used as a substitute for consulting with a qualified doctor.
In Bangladesh, Ocrevus is approved for the following indication(s)1:
OCREVUS is indicated for the treatment of patients with relapsing forms of multiple sclerosis (RMS) to suppress relapses and disease progression (clinical and subclinical disease activity).
OCREVUS is indicated for the treatment of patients with primary progressive multiple sclerosis (PPMS) to delay disease progression and reduce deterioration in walking speed.
For more disease and treatment related queries, it is recommended that you discuss with your physicians in details.
In Bangladesh, Ocrevus is available as
Vial 300 mg / 10 ml
To ensure patient safety and quality, it is strongly recommended to verify that, each medicine comes with the Roche Hologram Sticker, DGDA approved DAR (Drug Administration Registration) Number imprinted on it. Neither Radiant nor Roche Bangladesh takes liability of any other sources of products.
References
Ocrevus Product Information _ BD RO4964913_April 2022
This website contains information which is targeted to the people of Bangladesh and could contain product details or information otherwise not accessible or valid in your country. Roche Bangladesh is not responsible for accessing such information that may not be in accordance with legal, regulatory, registration or use processes in your home country. Please note that, information on this site is not intended as medical advice and should not be used as a substitute for consulting with qualified doctor. We are unable to answer questions on individual disease treatment/ management matters. These should be discussed with your physician. We cannot answer product-related questions through this website. Nor this site acts as promotional/ commercial tool for products. It is not permissible to take the contents of this site and use it for commercial purpose, without written consent of Roche Bangladesh.